These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2895317)

  • 1. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.
    Robinson WE; Montefiori DC; Mitchell WM
    Lancet; 1988 Apr; 1(8589):790-4. PubMed ID: 2895317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera.
    Robinson WE; Montefiori DC; Mitchell WM
    Biochem Biophys Res Commun; 1987 Dec; 149(2):693-9. PubMed ID: 3426595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
    Robey WG; Arthur LO; Matthews TJ; Langlois A; Copeland TD; Lerche NW; Oroszlan S; Bolognesi DP; Gilden RV; Fischinger PJ
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7023-7. PubMed ID: 3018753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.
    Weinhold KJ; Lyerly HK; Matthews TJ; Tyler DS; Ahearne PM; Stine KC; Langlois AJ; Durack DT; Bolognesi DP
    Lancet; 1988 Apr; 1(8591):902-5. PubMed ID: 2895830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
    Klasse PJ; Pipkorn R; Blomberg J
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5225-9. PubMed ID: 2455899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees.
    Robinson WE; Montefiori DC; Mitchell WM; Prince AM; Alter HJ; Dreesman GR; Eichberg JW
    Proc Natl Acad Sci U S A; 1989 Jun; 86(12):4710-4. PubMed ID: 2471977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies and the course of HIV-induced disease.
    Wendler I; Bienzle U; Hunsmann G
    AIDS Res Hum Retroviruses; 1987; 3(2):157-63. PubMed ID: 3650100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
    Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Jul; 259(2):416-27. PubMed ID: 10388665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.
    Lyerly HK; Reed DL; Matthews TJ; Langlois AJ; Ahearne PA; Petteway SR; Weinhold KJ
    AIDS Res Hum Retroviruses; 1987; 3(4):409-22. PubMed ID: 2833917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
    Müller B; Müller-Ruchholtz W
    Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of complement on the surface of cells infected by human immunodeficiency virus.
    Spear GT; Landay AL; Sullivan BL; Dittel B; Lint TF
    J Immunol; 1990 Feb; 144(4):1490-6. PubMed ID: 1968081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection.
    Lange JM; Paul DA; de Wolf F; Coutinho RA; Goudsmit J
    AIDS; 1987 May; 1(1):15-20. PubMed ID: 3122785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unconventional vaccines: immunization with anti-idiotype antibody against viral diseases.
    Koprowski H
    Cancer Res; 1985 Sep; 45(9 Suppl):4689s-4690s. PubMed ID: 2990707
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
    Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin drugs do not affect serum complement activation in vitro.
    Lappegård KT; Hvassing T; Mollnes TE
    Scand J Immunol; 2004; 60(1-2):178-83. PubMed ID: 15238087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection.
    Montefiori DC; Reimann KA; Letvin NL; Zhou J; Hu SL
    AIDS Res Hum Retroviruses; 1995 Aug; 11(8):963-70. PubMed ID: 7492443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses to the herpes simplex virus type 2 glycoprotein G in sera of human immunodeficiency virus-infected patients in Slovakia.
    Bystrická M; Soláriková L; Gasparíková L; Staneková D; Mokrás M; Kovácová E; Sabó A; Russ G
    Acta Virol; 1998 Nov; 42(5):319-24. PubMed ID: 10358733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro.
    Hosoi S; Borsos T; Dunlop N; Nara PL
    J Acquir Immune Defic Syndr (1988); 1990; 3(4):366-71. PubMed ID: 2313562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.